home / stock / vynt / vynt news

VYNT News and Press, Vyant Bio Inc. From 03/28/22

Stock Information
Company Name: Vyant Bio Inc.
Stock Symbol: VYNT
Market: NASDAQ
Website: vyantbio.com
Menu
VYNT VYNT Quote VYNT Short VYNT News VYNT Articles VYNT Message Board
Get VYNT Alerts

News, Short Squeeze, Breakout and More Instantly...
VYNT - Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021

CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...
VYNT - Vyant Bio Issues Letter to Shareholders

Cherry Hill, NJ, March 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics. Today Vyant Bio rele...

VYNT - Vyant Bio to Present at the H.C. Wainwright Bioconnect Conference

Cherry Hill, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) dis...

VYNT - Vyant Bio to Present at The Benchmark Company Discovery One-on-One Investor Conference

Cherry Hill, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS...
VYNT - Vyant Bio's (VYNT) CEO Jay Roberts on Q3 2021 Results - Earnings Call Transcript

Vyant Bio, Inc. (VYNT) Q3 2021 Earnings Conference Call November 11, 2021 4:30 PM ET Company Participants Jay Roberts – Chief Executive Officer Andy LaFrence – Chief Financial Officer Bob Fremeau – Chief Scientific Officer Conference Call Participants Ed White – H....

VYNT - Vyant Bio EPS in-line, misses on revenue

Vyant Bio (NASDAQ:VYNT): Q3 GAAP EPS of -$0.15 in-line. Revenue of $1.5M (+354.5% Y/Y) misses by $0.69M. Press Release For further details see: Vyant Bio EPS in-line, misses on revenue

VYNT - Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates

Strategic Highlights Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bio’s R&D programs targeting the identification of novel therapeutics Entered into two new first phase feasibility programs with leading biopharma companies to demonstrat...
VYNT - Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference

Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and onc...

VYNT - Vyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021

CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio , Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) an...

VYNT - BGVF, VYNT and SNMP among pre market gainers

Evaxion Biotech (NASDAQ:EVAX) +219%. TDH Holdings (NASDAQ:PETZ) +66%. NeoPhotonics NPTN +35% on Q3 earnings. QuinStreet QNST +26% on Q1 earnings. Artelo Biosciences (NASDAQ:ARTL) +22%. Concert Pharmaceuticals CNCE +25% signs agreement to raise $65M financing Cros...
Previous 10 Next 10